$TXG News

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $22

JP Morgan Maintains Neutral on 10x Genomics, Raises Price Target to $20

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

10x Genomics (NASDAQ:TXG) Beats Q1 Estimates But Falls as Revenue Shrinks Year-Over-Year

10x Genomics Affirms FY2026 Sales Guidance of $600.000M-$625.000M vs $613.107M Est.

10x Genomics Q1 EPS $(0.10) Beats $(0.30) Estimate, Sales $150.843M Beat $146.355M Estimate.

Should Launch of Atera Spatial Biology Platform Require Action From 10x Genomics (TXG) Investors?

10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?

10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference

1 Unprofitable Stock to Target This Week and 2 That Underwhelm

Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?

1 Cash-Heavy Stock to Target This Week and 2 We Ignore

LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $32

B of A Securities Maintains Neutral on 10x Genomics, Raises Price Target to $30

Reported Earlier, 10x Genomics Announced Atera, A New In Situ Spatial Biology Platform Engineered To Deliver Whole-transcriptome Spatial Analysis With Single-cell Sensitivity At Unprecedented Scale

10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood

10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026

Keys to Succeed in the Booming $300 Million Optical Genome Mapping Market 2026-2030: Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies Lead